mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

Cancer Cell

Volumn 15, Issue 2, 2009, Pages 148-159

  Guertin, David A ^a,b   Stevens, Deanna M ^a   Saitoh, Maki ^a,b   Kinkel, Stephanie ^a,b   Crosby, Katherine ^c   Sheen, Joon Ho ^a,b   Mullholland, David J ^d   Magnuson, Mark A ^e   Wu, Hong ^d   Sabatini, David M ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c CELL SIGNALING TECHNOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE DELETION; HETEROZYGOSITY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEFICIENCY;

MAMMALIA; MUS; MUS MUSCULUS;

EID: 58649114084     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.12.017     Document Type: Article

References (56)

1. Abraham R.T., and Eng C.H. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets 12 (2008) 209-222
2. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., and Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15 (1996) 6541-6551
3. Backman S.A., Stambolic V., Suzuki A., Haight J., Elia A., Pretorius J., Tsao M.S., Shannon P., Bolon B., Ivy G.O., and Mak T.W. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29 (2001) 396-403
4. Bayascas J.R., Leslie N.R., Parsons R., Fleming S., and Alessi D.R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr. Biol. 15 (2005) 1839-1846
5. Bhaskar P.T., and Hay N. The two TORCs and Akt. Dev. Cell 12 (2007) 487-502
6. Biondi R.M., Kieloch A., Currie R.A., Deak M., and Alessi D.R. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 20 (2001) 4380-4390
7. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
8. Bozulic L., Surucu B., Hynx D., and Hemmings B.A. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 30 (2008) 203-213
9. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., and Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20 (2006) 1569-1574
10. Chiang G.G., and Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 13 (2007) 433-442
11. Collins B.J., Deak M., Arthur J.S., Armit L.J., and Alessi D.R. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22 (2003) 4202-4211
12. Dahia P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 7 (2000) 115-129
13. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
14. Facchinetti V., Ouyang W., Wei H., Soto N., Lazorchak A., Gould C., Lowry C., Newton A.C., Mao Y., Miao R.Q., et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27 (2008) 1932-1943
15. Freeman D., Lesche R., Kertesz N., Wang S., Li G., Gao J., Groszer M., Martinez-Diaz H., Rozengurt N., Thomas G., et al. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res. 66 (2006) 6492-6496
16. Frias M.A., Thoreen C.C., Jaffe J.D., Schroder W., Sculley T., Carr S.A., and Sabatini D.M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16 (2006) 1865-1870
17. Garcia-Martinez J.M., and Alessi D.R. mTOR complex-2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum and glucocorticoid induced protein kinase-1 (SGK1). Biochem. J. 416 (2008) 375-385
18. Guertin D.A., and Sabatini D.M. Defining the Role of mTOR in Cancer. Cancer Cell 12 (2007) 9-22
19. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., and Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006) 859-871
20. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim. Biophys. Acta 1697 (2004) 3-16
21. Hietakangas V., and Cohen S.M. Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. Genes Dev. 21 (2007) 632-637
22. Hresko R.C., and Mueckler M. mTOR/RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280 (2005) 40406-40416
23. Huang B., and Porter G. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Acta Pharmacol. Sin. 26 (2005) 1253-1258
24. Ikenoue T., Inoki K., Yang Q., Zhou X., and Guan K.L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27 (2008) 1919-1931
25. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., and Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
26. Jiao J., Wang S., Qiao R., Vivanco I., Watson P.A., Sawyers C.L., and Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 67 (2007) 6083-6091
27. Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
28. Kovacina K.S., Park G.Y., Bae S.S., Guzzetta A.W., Schaefer E., Birnbaum M.J., and Roth R.A. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278 (2003) 10189-10194
29. Kumar A., Harris T.E., Keller S.R., Choi K.M., Magnuson M.A., and Lawrence Jr. J.C. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol. Cell. Biol. 28 (2008) 61-70
30. Lee S., Comer F.I., Sasaki A., McLeod I.X., Duong Y., Okumura K., Yates III J.R., Parent C.A., and Firtel R.A. TOR complex 2 integrates cell movement during chemotaxis and signal relay in Dictyostelium. Mol. Biol. Cell 16 (2005) 4572-4583
31. Lei Q., Jiao J., Xin L., Chang C.J., Wang S., Gao J., Gleave M.E., Witte O.N., Liu X., and Wu H. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9 (2006) 367-378
32. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004) 399-403
33. Manning B.D., and Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 129 (2007) 1261-1274
34. Masri J., Bernath A., Martin J., Jo O.D., Vartanian R., Funk A., and Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67 (2007) 11712-11720
35. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R.A., Shiojima I., Nagy J.A., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
36. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96 (1999) 1563-1568
37. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16 (2004) 564-575
38. Salmena L., Carracedo A., and Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 133 (2008) 403-414
39. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., and Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25 (2007) 903-915
40. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
41. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
42. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
43. Sellers W.R., and Sawyers C.L. Somatic Genetics of Prostate Cancer: Oncogenes and Tumor Suppressors (2002), Lippincott Williams & Wilkins, Philadelphia
44. Shiota C., Woo J.T., Lindner J., Shelton K.D., and Magnuson M.A. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11 (2006) 583-589
45. Shor B., Zhang W.G., Toral-Barza L., Lucas J., Abraham R.T., Gibbons J.J., and Yu K. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 68 (2008) 2934-2943
46. Skeen J.E., Bhaskar P.T., Chen C.C., Chen W.S., Peng X.D., Nogueira V., Hahn-Windgassen A., Kiyokawa H., and Hay N. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10 (2006) 269-280
47. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
48. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., and Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58 (1998) 204-209
49. Tessier M., and Woodgett J.R. Serum and glucocorticoid-regulated protein kinases: variations on a theme. J. Cell. Biochem. 98 (2006) 1391-1407
50. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1 (2003) E59
51. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., and Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9 (2007) 316-323
52. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16 (2005) 525-537
53. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003) 209-221
54. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., Sangiorgi F.O., Maxson R.E., Sucov H.M., and Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101 (2001) 61-69
55. Yang Q., Inoki K., Ikenoue T., and Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20 (2006) 2820-2832
56. Zeng Z., Sarbassov D.D., Samudio I.J., Yee K.W., Munsell M.F., Jackson C.E., Giles F.J., Sabatini D.M., Andreeff M., and Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109 (2006) 3509-3512